-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Biotech Secures South Korean Patent Allowance for Annamycin Reconstitution

PUBT·11/18/2026 13:37:16
Moleculin Biotech Secures South Korean Patent Allowance for Annamycin Reconstitution
  • Moleculin Biotech received South Korean patent allowance for its method of reconstituting liposomal Annamycin.
  • The allowance expands an Annamycin patent portfolio covering three technology areas across more than 20 jurisdictions.
  • Annamycin is being evaluated with cytarabine in the pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180835PRIMZONEFULLFEED9880346) on November 18, 2026, and is solely responsible for the information contained therein.